SZOXF yields 28.53% · JNJ yields 2.13%● Live data
📍 SZOXF pulled ahead of the other in Year 1
Combined, SZOXF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SZOXF + JNJ for your $10,000?
This ETN was delisted on April 11, 2019, and now trades over-the-counter on the pink sheets. As a result, shareholders should anticipate ultra-wide spreads, minimal trading volumes, and prices well above or below NAVs. SZO is, like most leveraged and inverse products, designed to provide -1x exposure to its index only with its monthly reset period. Investors holding it beyond the next monthly reset date will be subject to the effects of compoundinga dynamic that can cause the note`s performance to drift from its promised -1x exposure. The note`s index tracks a single futures contract on light sweet crude oil determined to be least influenced by contango. The index measures the changes in price of the oil futures contract, the returns from rolling those contracts over, and the cost of borrowing (collateral) as measured by the 3-month Treasury bill. Although its 75 bp fee is entirely reasonable compared with other inverse products, trading costs are of greater importance, since SZO is designed for round-trip intraday trading. To that end, the market for SZO is both shallow and wide, with very little trading volume, at too-wide spreads. Investors interested in inverse oil ETPs will find better liquidity in DNO or DTO.
Full SZOXF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.